An Ophthalmic Safety Study in Patients With Breast Cancer
NCT ID: NCT06767462
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
160 participants
OBSERVATIONAL
2025-03-04
2027-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors
NCT07258108
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
NCT03390894
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
NCT05190094
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
NCT03439046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To be able to account for events associated with aging, worsening of pre-existing conditions, etc., ophthalmic study assessments will be performed in parallel in two cohorts at the same timepoints. The duration of the study assessment period will be approximately 12 months. Longer duration of the study would result in additional patient burden.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 from Qualifying Study
No interventions assigned to this group
Cohort 2 from Qualifying Study
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
4. Meets all the eligibility criteria in the qualifying study
Exclusion Criteria
2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
La Jolla, California, United States
Research Site
Palo Alto, California, United States
Research Site
San Diego, California, United States
Research Site
Iowa City, Iowa, United States
Research Site
New York, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Cleveland, Ohio, United States
Research Site
Clairton, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Sioux Falls, South Dakota, United States
Research Site
Bartlett, Tennessee, United States
Research Site
Houston, Texas, United States
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
Córdoba, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
Edegem, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Alfenas, , Brazil
Research Site
Belo Horizonte, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Lajeado, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Pouso Alegre, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Sorocaba, , Brazil
Research Site
Três Lagoas, , Brazil
Research Site
Vitória, , Brazil
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Bordeaux Cédex, , France
Research Site
Caen, , France
Research Site
Nantes, , France
Research Site
Poitiers, , France
Research Site
Suresnes, , France
Research Site
Ashdod, , Israel
Research Site
Nahariya, , Israel
Research Site
Milan, , Italy
Research Site
Aguascalientes, , Mexico
Research Site
Mexico City, , Mexico
Research Site
San Pedro Garza García, , Mexico
Research Site
Veracruz, , Mexico
Research Site
Lodz, , Poland
Research Site
Nowa Sól, , Poland
Research Site
Amadora, , Portugal
Research Site
Braga, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Seoul, , South Korea
Research Site
Badalona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Girona, , Spain
Research Site
L'Hospitalet de Llobregat, , Spain
Research Site
Leganés, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Salamanca, , Spain
Research Site
Sant Joan Despí, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D853AC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.